Search results for Mosunetuzumab ELISA Kit
Mosunetuzumab ELISA Kit, ProteoGenix, KPTX178
Description of Mosunetuzumab ELISA Kit Introduction The Mosunetuzumab ELISA Kit is a highly sensitive and specific tool used for the detection and quantification of Mosunetuzumab, a novel bispecific antibody targeting CD3 and CD20. This kit is an essential component in the development and evaluation of Mosunetuzumab, a promising therapeutic agent for the treatment of B-cell malignancies. Structure of Mosunetuzumab Mosunetuzumab is a bispecific antibody that simultaneously binds to both CD3 and CD20 on the surface of B-cells. It is composed of two single-chain variable fragments (scFv) targeting CD3 and CD20, connected by a flexible linker. This unique structure allows for the simultaneous activation of T-cells through CD3 and the depletion of B-cells through CD20, resulting in a potent anti-tumor effect. Activity of Mosunetuzumab Mosunetuzumab has shown promising activity in preclinical studies, with potent anti-tumor effects in various B-cell malignancies such as non-Hodgkin lymphoma and chronic lymphocytic leukemia. It has also demonstrated superior activity compared to other CD3-CD20 bispecific antibodies, due to its unique structure and binding affinity. The mechanism of action of Mosunetuzumab involves the activation of T-cells and the subsequent killing of B-cells through the formation of immunological synapses. This results in the release of cytotoxic granules and the induction of apoptosis in the targeted B-cells. In addition, Mosunetuzumab has been shown to have a longer half-life and increased stability compared to other bispecific antibodies, making it a more effective therapeutic agent. Application of Mosunetuzumab ELISA Kit The Mosunetuzumab ELISA Kit is a crucial tool for the development and evaluation of Mosunetuzumab as a therapeutic agent. It allows for the quantification of Mosunetuzumab levels in various biological samples, such as serum, plasma, and cell culture supernatants. This kit is also used in pharmacokinetic studies to determine the absorption, distribution, metabolism, and excretion of Mosunetuzumab in vivo. It provides accurate and reliable data on the pharmacokinetic profile of Mosunetuzumab, which is essential for the optimization of dosage and treatment regimens. In addition, the Mosunetuzumab ELISA Kit is a valuable tool for monitoring the efficacy of Mosunetuzumab in clinical trials. It allows for the quantification of Mosunetuzumab levels in patient samples, which can be correlated with clinical outcomes. This enables researchers to assess the relationship between drug exposure and response, and to identify potential biomarkers for patient selection and treatment response. Conclusion The Mosunetuzumab ELISA Kit is a highly sensitive and specific tool for the detection and quantification of Mosunetuzumab, a novel bispecific antibody targeting CD3 and CD20. Its unique structure and potent activity make it a promising therapeutic agent for the treatment of B-cell malignancies. The application of this kit in the development and evaluation of Mosunetuzumab is crucial for its successful translation into clinical practice.
Host
Reactivity
Applications
Conjugation
Mosunetuzumab ELISA Kit, Abbexa, abx395067
This product is currently in development. The lead time for this product may be several months. Please contact us at [email protected] for an updated lead time before purchasing this product. Mosunetuzumab ELISA Kit is a quantitative ELISA kit for detection of Mosunetuzumab.Polatuzumab vedotin is an active ingredient of Polivy, a drug product for the treatment of previously treated adult patients with diffuse large B-cell lymphoma (DLBCL) in combination with bendamustine and rituximab. Polatuzumab vedotin is an antibody-drug conjugate composed of a humanized monoclonal antibody (mAb) targeting B-cell antigen receptor complex-associated protein beta chain (CD79b) and a microtubule-disrupting toxin, monomethyl auristatin E (MMAE). This drug was developed by Genentech/Roche using a proprietary technology developed by Seattle Genetics. In 2018, orphan designation was granted for polatuzumab vedotin for the treatment of diffuse large B-cell lymphoma by the European Commission to Roche Registration Limited. Based on the effective therapeutic effect of polatuzumab vedotin on DLBCL, the U.S. Food and Drug Administration (FDA) granted accelerated approval to polatuzumab vedotin, in combination with bendamustine plus rituximab on 10 June 2019. Subsequently, the European Medicines Health and Therapeutic Goods Administration of Australian Drug Regulatory Administration also approved Polivy's sales authorization from Genentech. Besides DLBCL, polatuzumab vedotin also has been investigated in the treatment of non-hodgkins lymphoma, chronic lymphocytic leukemia, follicular lymphoma. Some of the trials were complicated, and there are six clinical trials still undergoing now. For example, there is a phase Ib/II study investigating the safety, tolerability, pharmacokinetics, and efficacy of mosunetuzumab (BTCT4465A) in combination with chop or chp-polatuzumab vedotin in participants with b-cell non-hodgkin lymphoma. Furthermore, a study to evaluate the safety and efficacy of polatuzumab vedotin in combination with rituximab, gemcitabine and oxaliplatin compared to rituximab, gemcitabine and oxaliplatin alone in participants with relapsed or refractory diffuse large B-cell lymphoma is recruiting. The recent events of polatuzumab vedotin is that Chugai Pharmaceutical, another developer, adverse events data from a phase ii (jo40762/p-drive) trial diffuse large B-cell lymphoma and announces intention to submit NDA to Ministry of Health, Labour and Welfare for diffuse large B-cell lymphoma in Japan on February 2020. At the same period, a phase-II clinical trials in diffuse large B cell lymphoma is undergoing in United Kingdom (IV).
Host
Reactivity
Human
Applications
ELISA
Conjugation
Please provide the required information below so that we can quickly source your products.